

**AWARD NUMBER:** W81XWH-22-1-0390

**TITLE:** Deciphering the Role of Progesterone in Ovarian Cancer Risk for BRCA Mutation Carriers

**PRINCIPAL INVESTIGATOR:** Jaeyeon Kim

**CONTRACTING ORGANIZATION:** Indiana University, Bloomington, IN

**REPORT DATE:** June 2023

**TYPE OF REPORT:** Annual

**PREPARED FOR:** U.S. Army Medical Research and Development Command  
Fort Detrick, Maryland 21702-5012

**DISTRIBUTION STATEMENT:** Approved for public release; Distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

<b>1. REPORT DATE</b>		<b>2. REPORT TYPE</b>		<b>3. DATES COVERED</b>	
<b>4. TITLE AND SUBTITLE</b>				<b>5a. CONTRACT NUMBER</b>	
				<b>5b. GRANT NUMBER</b>	
				<b>5c. PROGRAM ELEMENT NUMBER</b>	
<b>6. AUTHOR(S)</b>				<b>5d. PROJECT NUMBER</b>	
				<b>5e. TASK NUMBER</b>	
E-Mail:				<b>5f. WORK UNIT NUMBER</b>	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b>				<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b>				<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>	
U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012				<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>	
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b>					
Approved for Public Release; Distribution Unlimited					
<b>13. SUPPLEMENTARY NOTES</b>					
<b>14. ABSTRACT</b>					
<b>15. SUBJECT TERMS</b>					
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>	<b>18. NUMBER OF PAGES</b>	<b>19a. NAME OF RESPONSIBLE PERSON</b>
<b>a. REPORT</b>	<b>b. ABSTRACT</b>	<b>c. THIS PAGE</b>			USAMRDC
Unclassified	Unclassified	Unclassified	Unclassified		<b>19b. TELEPHONE NUMBER</b> (include area code)

## TABLE OF CONTENTS

	<u>Page</u>
1. Introduction	4
2. Keywords	4
3. Accomplishments	4
4. Impact	9
5. Changes/Problems	9
6. Products	9
7. Participants & Other Collaborating Organizations	9
8. Special Reporting Requirements	10
9. Appendices	10

**1. INTRODUCTION:** The central hypothesis of this project is that ovarian progesterone (P4) is a crucial intrinsic factor determining ovarian cancer risk among *BRCA1/2*-mutation carriers. The specific hypotheses are: (1) P4 is a vital *early* factor inducing HGSC development and metastasis; and (2) genetic alterations impacting P4 levels determine individual ovarian cancer risks in *BRCA1/2* carriers. To test these hypotheses, we will examine the early role of ovarian P4, and the blocking effect of P4 signaling by an antiprogestin, in the development and metastasis of HGSC using a *Brca1* mouse model; and comprehensively evaluate the genomic and metabolomic factors that influence steroid hormone synthesis and metabolism in *BRCA1/2*-mutation carriers.

**2. KEYWORDS:** Ovarian cancer, high-grade serous carcinoma, high-grade serous ovarian cancer, HGSC, BRCA1, BRCA2.

**3. ACCOMPLISHMENTS:**

<b>Specific Aim 1:</b> Evaluate whether P4 is a vital early factor determining HGSC development and metastasis	<b>Timeline (Months)</b>	<b>Site 1 (IUSM)</b>	<b>Site 2 (Georgia Tech)</b>	<b>Current Status</b>
<b>Major Task 1</b> Hypothesis: early P4 exposure is vital to development of HGSC and acquiring its metastatic potential.				
Subtask 1: Effect of early, short-term P4 exposure on HGSC development and metastasis. <ul style="list-style-type: none"> <li>• Submission of institution approved animal protocols and related material for DoD's ACURO approval.</li> <li>• Receive ACURO approval before initiating animal experiments.</li> <li>• 20 mice per group x 8 groups = 160 mice total.</li> </ul>	1-24	x		Necessary animal protocol has been approved by IUSM IACUC and DoD ACURO Mouse breeding and generation is in progress to obtain experimental mice
Subtask 2: P4- and mifepristone-specific early molecular alterations in HGSC development <ul style="list-style-type: none"> <li>• Submission of institution approved animal protocols and related material for DoD's ACURO approval.</li> <li>• Receive ACURO approval before initiating animal experiments.</li> <li>• 5 mice per group x 12 groups = 60 mice total.</li> </ul>	1-24	x		Necessary animal protocol has been approved by IUSM IACUC and DoD ACURO Mouse breeding and generation is in progress to obtain experimental mice
<i>Milestone(s) Achieved:</i> Determination of a critical role of P4 in HGSC initiation; characterization of early molecular changes in P4-induced HGSC development.	24			
<b>Major Task 2</b> Hypothesis: Blocking P4 signaling early for a short period effectively inhibits HGSC development and metastases.				
Subtask 1: Preventive effect of early, short-term blocking of P4 signaling with the antiprogestin mifepristone.	12-36	x		

<ul style="list-style-type: none"> <li>• Submission of institution approved animal protocols and related material for DoD's ACURO approval.</li> <li>• Receive ACURO approval before initiating animal experiments.</li> <li>• 20 mice per group x 6 groups = 120 mice total.</li> </ul>				
<p>Subtask 2: Inhibitory effect of mifepristone on transformation of premalignant fallopian tube cells</p> <ul style="list-style-type: none"> <li>• Submission of institution approved animal protocols and related material for DoD's ACURO approval.</li> <li>• Receive ACURO approval before initiating animal experiments.</li> <li>• 5 mice per group x 4 groups x 3 repeats = 60 mice total.</li> </ul>	12-30	x		
<p><i>Milestone(s) Achieved:</i> Determination of the preventive effect of short-term antiprogestin intervention on ovarian cancer.</p>	36			
<p><b>Specific Aim 2:</b> Define genetic factors affecting steroid hormone levels in <i>BRCA1/2</i>-mutation carriers</p>	<b>Timeline (Months)</b>	<b>Site 1 (IUSM)</b>	<b>Site 2 (Georgia Tech)</b>	
<p><b>Major Task 1</b> hypothesis: <i>BRCA</i>-mutation carriers may harbor additional genomic abnormalities affecting steroidogenesis.</p>				
<p>Subtask 1: Examine genomic alterations affecting steroidogenesis among <i>BRCA</i>-mutation carriers.</p> <ul style="list-style-type: none"> <li>• Whole-exome sequencing (WES) analysis using genomic DNA samples from 70 unaffected and 70 affected <i>BRCA</i> carriers as well as 50 sporadic HGSC cases.</li> <li>• IRB protocol not required: de-identified, tissue-bank human samples were determined as Not Human Subjects Research by IRB.</li> </ul> <p>Subtask 2: Association between hormone levels and ovarian cancer development.</p>	6-48	x		Early stages: in collaboration with IUSCCC Komen Tissue Bank (KTB), DNA sequencing data of <i>BRCA</i> carriers is being analyzed.
<p><i>Milestone(s) Achieved:</i> Identification of specific genomic alterations associated with hormone synthesis and response; Publication of 1-2 peer-reviewed papers.</p>	48			
<p><b>Major Task 2</b> hypothesis: Different levels of progesterone (P4) elicit distinct metabolomic changes.</p>				

<p>Subtask 1: Assess metabolomic alterations associated with P4 levels and steroidogenesis in a <i>Brca1</i> mouse model and among <i>BRCA</i> carriers by mass spectrometry analysis.</p> <ul style="list-style-type: none"> <li>• Serum samples from the mouse studies from Specific Aim 1 Major Task 1 and 2: 340 samples total.</li> <li>• Serum samples from Specific Aim 2 Major Task 1: 190 samples total.</li> </ul> <p>Subtask 2: Development of in-depth steroidomics analysis to quantify metabolites in the steroid biosynthesis pathway.</p>	1-48		x	Early stages: Analytic pipeline for in-depth steroidomics is under development
<p><i>Milestone(s) Achieved:</i> Determination of specific metabolites linked to different levels of P4; Mapping the abundance of all metabolites in the P4 biosynthesis pathway.</p>	48			

## Abbreviations

**ACURO:** Animal Care and Use Review Office

**BRCA1:** Breast Cancer 1 gene.

**BRCA1/2:** Breast Cancer 1 or 2 gene.

**BRCA carriers:** women carrying a pathogenic BRCA1 or 2 mutation.

**HGSC:** high-grade serous carcinoma, or high-grade serous ovarian cancer.

**IUSM:** Indiana University School of Medicine

**IUSCCC:** Indiana University Simon Comprehensive Cancer Center

**P4:** progesterone.

## What was accomplished under the goals?

In the first year of the project, we had made expected progress in line with the goals laid out in the SOW. We had obtained the IUSM IACUC and DoD ACURO approval for mouse experiments. Mouse breeding had been progressing accordingly without any major issues or obstacles. Also, DNA sequencing analysis had been initiated using whole-genome sequencing (WGS) data from BRCA1 or 2 carriers and women without these mutations. Additionally, we have begun to develop an analytical liquid chromatography-mass spectrometry (LC-MS/MS) pipeline for in-depth steroidomics of animal serum using mass spectrometry.

**Specific Aim 1:** Evaluate whether P4 is a vital early factor determining HGSC development and metastasis.

To examine the hypothesis that early P4 exposure is critical to HGSC development and its metastatic potential, we have been in the process of generating the experimental female mice: *Brca1*<sup>+/-</sup>-DKO mice (*Brca1*<sup>flox/+</sup> *Dicer1*<sup>flox/flox</sup> *Pten*<sup>flox/flox</sup> *Amhr2*<sup>cre/+</sup>). To generate these experimental mice, we have also been generated breeding pairs with proper genotypes: male *Brca1*<sup>flox/+</sup> *Dicer1*<sup>flox/flox</sup> *Pten*<sup>flox/flox</sup> *Amhr2*<sup>cre/+</sup> mice; female *Brca1*<sup>+/+</sup> *Dicer1*<sup>flox/flox</sup> *Pten*<sup>flox/flox</sup> *Amhr2*<sup>+/+</sup> mice. With a steady flow of active breeding pairs being established, we expect to produce a total of 400 experimental mice throughout the project period.

**Specific Aim 2:** Define genetic factors affecting steroid hormone levels in *BRCA1/2*-mutation carriers.

BRCA1/2 carriers have high genetic risks of developing ovarian and breast cancer. Despite the high risks, not all BRCA1/2 carriers develop these cancers. Incomplete penetrance suggests that additional modifying factors (genetic, environmental, or both) are necessary for oncogenesis in BRCA1/2 carriers. Our previous research suggests that ovarian progesterone (P4) may be a critical determinant of cancer development in BRCA1/2 carriers. Thus, we hypothesize that BRCA1/2 carriers may harbor additional genomic abnormalities affecting steroidogenesis.

One gene of interest is CYP21A2, which encodes 21 $\alpha$ -hydroxylase. This enzyme converts (i) P4 to 11-deoxycorticosterone and (ii) 17 $\alpha$ -hydroxyprogesterone (17 $\alpha$ -OHP4) to 11-deoxycortisol. Thus, defects in this enzyme leads to an accumulation of P4 and 17 $\alpha$ -OHP4, which could enhance P4 signaling. Interestingly, mutations in the CYP21A2 gene are common in Ashkenazi Jews (1 in 3), who also have high incidence of BRCA1/2 mutations (1 in 40 women; 1:400 in the general population). Thus, we hypothesize that BRCA1/2 carriers might be more likely to harbor CYP21A2 mutations than women without BRCA1/2 mutations.

To test this hypothesis, we have first sought to examine CYP21A2 mutations in unaffected BRCA1/2 carriers and affected BRCA1/2 carriers with breast cancer as well as women negative for these BRCA1/2 mutations, in collaboration with the Komen Tissue Bank (KTB) at IUSCCC. We are currently analyzing WGS data from 51 BRCA1/2 carriers and 410 women negative for BRCA1/2 mutations. This hypothesis would be supported if the proportion of BRCA1/2 carriers with CYP21A2 mutations is significantly higher than that of BRCA1/2-negative women with CYP21A2 mutations. We will report the results in the year 2 progress report.

To examine both metabolism products and reactants in the progesterone signaling pathway, we have surveyed the cancer literature and compiled a list of target analytes that we will quantify using chemical standards as well as high resolution accurate mass tandem mass spectrometry. We are currently in the process of sourcing these standards from a number of chemical vendors and have started to optimize the conditions for ionization of these analytes using atmospheric pressure chemical ionization in an Orbitrap system. The next steps will be to construct external calibration curves for each analyte alone and in combination, followed by investigation of pilot animal serum samples in their native form as well as spiked with the target analytes. Recovery calculations will be performed and the method optimized as needed.

### **What opportunities for training and professional development has the project provided?**

This project has allowed our lab and me to initiate collaborations with other investigators within the institution, nationally, and internationally. We have recruited a new graduate student to the project and she is being trained in metabolomics and lipidomics methodologies.

### **What do you plan to do during the next reporting period to accomplish the goals?**

**Specific Aim 1:** Evaluate whether P4 is a vital early factor determining HGSC development and metastasis.

Major Task 1 Hypothesis: early P4 exposure is vital to HGSC development and its metastatic potential.

Subtask 1: Effect of early, short-term P4 exposure on HGSC development and metastasis.

To test whether early P4 exposure is crucial to HGSC development and metastasis, we will treat Brca1<sup>+/-</sup>-DKO mice with P4 (or a placebo) for 3 wk (6 mg total) at a different time point after ovariectomy: (i) upon ovariectomy at 5-6 wk of age, (ii) 1 week after ovariectomy, (iii) 3 wk after ovariectomy, or (iv) 3 months (m) after ovariectomy (20 mice in each group). Tumor development and metastasis will be examined using histopathological and molecular analyses.

Subtask 2: P4- and mifepristone-specific early molecular alterations in HGSC development.

To capture the P4-specific early molecular alterations leading to HGSC development, *Brcal*<sup>+/-</sup>-DKO mice will be treated with P4 or mifepristone for variable lengths (1 wk to 3 m). In this experiment, *Brcal*<sup>+/-</sup>-DKO mice, upon ovariectomy at 5-6 weeks of age, will be treated with P4 or a placebo: (i) 1 wk (2 mg total), (ii) 3 wk (6 mg), or (iii) 3 m (25 mg). In parallel, *Brcal*<sup>+/-</sup>-DKO mice, without ovariectomy, will be treated at 5-6 weeks of age with mifepristone or a placebo: (i) 1 wk (0.7 mg), (ii) 3 wk (2.1 mg), or (iii) 3 m (9 mg). (12 groups; 5 mice/group.) Mice in each group will be sacrificed at 1 wk, 3 wk, or 3 m after treatment. Premalignant or tumor tissues in the fallopian tube will be used for RNA-Seq analysis.

**Major Task 2 Hypothesis:** Blocking P4 signaling early for a short period effectively inhibits HGSC development and metastases

Subtask 1: Preventive effect of early, short-term blocking of P4 signaling with the antiprogestin mifepristone

To assess whether blocking P4 signaling early for a short period is sufficient for HGSC prevention, we will treat *Brcal*<sup>+/-</sup>-DKO mice with the antiprogestin mifepristone for variable lengths at a premalignant stage. In this experiment, *Brcal*<sup>+/-</sup>-DKO mice will be treated with mifepristone (or a placebo), starting at 5-6 wk of age, for 1 wk (0.7 mg), 3 wk (2.1 mg), or 3 m (9 mg) (20 mice in each group). Mouse survival as well as tumor development will be examined. This experiment will likely begin toward the end of year 2.

Subtask 2: Inhibitory effect of mifepristone on transformation of premalignant fallopian tube cells

We will establish primary premalignant fallopian tube cultures using *Brcal*<sup>+/-</sup>-DKO mice.

**Specific Aim 2:** Define genetic factors affecting steroid hormone levels in *BRCA1/2*-mutation carriers.

**Major Task 1 hypothesis:** *BRCA*-mutation carriers may harbor additional genomic abnormalities affecting steroidogenesis.

Subtask 1: Examine genomic alterations affecting steroidogenesis among *BRCA*-mutation carriers.

In addition to examining the correlation between *BRCA1/2* mutations and *CYP21A2* mutations, we will also determine whether *CYP21A2* mutations are correlated with increased risk of breast cancer in *BRCA1/2* carriers, using the KTB WGS data. Besides *CYP21A2* mutations, we will also examine other gene variants, including progesterone receptor variants, which are linked to steroidogenesis, to evaluate the potential contributions to cancer risks in *BRCA1/2* carriers. We will also expand this analysis to ovarian cancer risk in *BRCA1/2* carriers.

Subtask 2: Association between hormone levels and ovarian cancer development.

To examine whether serum P4 levels correlate with ovarian cancer development among *BRCA1/2* carriers, we will begin to obtain serum samples, via collaboration, from unaffected carriers (*BRCA*-mutation carriers without cancer) and affected carriers (*BRCA*-mutation carriers diagnosed with ovarian or breast cancer).

**Major Task 2 hypothesis:** Different levels of progesterone (P4) elicit distinct metabolomic changes.

Subtask 1: Assess metabolomic alterations associated with P4 levels and steroidogenesis in a *Brcal* mouse model and among *BRCA* carriers by mass spectrometry analysis.

Serum samples will be collected from *Brcal*<sup>+/-</sup>-DKO mice with or without P4 or mifepristone. Serum samples obtained from Aim 2 Main Task 1 (Subtask 2) will also be used for metabolomics analysis, which will be performed once all samples are collected.

Subtask 2: Development of in-depth steroidomics analysis to quantify metabolites in the steroid biosynthesis pathway.

Quantitation of a number of metabolites in the progesterone signaling pathway will be achieved using LC-MS/MS approaches. These methods will be carefully validated to ensure the accuracy and precision of the results.

**4. IMPACT: *Nothing to Report.***

**5. CHANGES/PROBLEMS: *Nothing to Report.***

**6. PRODUCTS: *Nothing to Report.***

## **7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS**

### **What individuals have worked on the project?**

Name: Jaeyeon Kim

Project Role: Principal Investigator

Contribution to Project: Dr. Kim has designed and supervised the project.

Name: Soojin Park

Project Role: Postdoctoral researcher

Contribution to Project: Dr. Park has performed mouse experiments as well as mouse management.

Name: Thu-Huyen Pham

Project Role: Postdoctoral researcher

Contribution to Project: Dr. Pham has performed mouse experiments as well as mouse management.

Name: Andro Botros

Project Role: Research Assistant

Contribution to Project: Mr. Botros has performed mouse genotyping as well as mouse management.

Name: Nicole Harris

Project Role: Research Assistant

Contribution to Project: Ms. Harris has performed mouse genotyping.

Name: Emily Massa

Project Role: Research Assistant

Contribution to Project: Ms. Massa has performed mouse genotyping.

Name: Elisabeth Schwiebert

Project Role: Graduate student (Georgia Institute of Technology)

Contribution to Project: Elisabeth is developing the LC-MS/MS steroidomics method.

Name: Dr. Facundo Fernández

Project Role: Partnering PI (Georgia Institute of Technology)

Contribution to Project: Dr. Fernández has designed and supervised the steroidomics analysis of the project.

**Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?** Nothing to Report.

**What other organizations were involved as partners?**

Organization Name: Georgia Institute of Technology.

Location of Organization: Atlanta, Georgia.

Partner's contribution to the project: Collaboration.

## **8. SPECIAL REPORTING REQUIREMENT**

**COLLABORATIVE AWARDS:** Dr. Facundo Fernández, the Partnering PI at Georgia Institute of Technology, will submit his Annual Report separately.

**9. APPENDICES:** None.